Celcuity Inc. (CELC)
| Previous Close | 16.30 |
| Open | 16.46 |
| Bid | 17.34 x 100 |
| Ask | 17.75 x 100 |
| Day's Range | 16.45 - 17.61 |
| 52 Week Range | 8.39 - 22.19 |
| Volume | |
| Avg. Volume | 236,454 |
| Market Cap | 533.843M |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.60 |
GlobeNewswireCelcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast w
Simply Wall St.Celcuity Gains 12%, Insider Trades Reap Benefit
Insiders who bought Celcuity Inc. ( NASDAQ:CELC ) stock in the last 12 months were richly rewarded last week. The...
Insider MonkeyCelcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript March 27, 2024 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.65, expectations were $-0.71. CELC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to […]
